Sernova Corp's latest earnings report shows steady performance amid ongoing developments in the biotechnology sector.
On September 10, 2026, Sernova Corp (SVA.TO) reported its fiscal results for the period ending July 31, 2026. The company posted an earnings per share (EPS) of -$0.01, which matches analyst estimates and reflects a consistent trend in recent quarters. This is the third consecutive quarter where Sernova's EPS has aligned with expectations, indicating stability in its financial performance despite ongoing challenges in the biotechnology landscape.
Recent earnings trend
Advertisement
Sernova Corp
SVA.TO
SVA.TO
Sernova Corp
WealthAwesomeMarket cap
$52.87M
52W high
$0.20
52W low
$0.10
1W change
+21.74%
Beta
0.64
Analyst Price Targets
Based on analyst covering SVA
Wall Street analysts forecast SVA stock price to rise 614.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$1.00
+614.3% Upside
Current Price
C$0.14
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on SVA's historical volatility
30-Day Vol
71.9%
Annualized
90-Day Vol
87.0%
Annualized
Trend (90d)
-42.7%
Annualized drift
90d Mean
C$0.12
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.13 | C$0.10 โ C$0.17 |
| 60 trading days | C$0.13 | C$0.09 โ C$0.18 |
| 90 trading days | C$0.12 | C$0.08 โ C$0.18 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-07-31 | 2026-09-10 | -0.0100 | -0.0100 | +0.0% |
| 2026-04-30 | 2026-06-11 | -0.0100 | -0.0100 | +0.0% |
| 2026-01-31 | 2026-03-13 | -0.0100 | -0.0100 | +0.0% |
| 2025-10-31 | 2025-12-19 | -0.0100 | -0.0100 | +0.0% |
| 2025-07-31 | 2025-09-15 | -0.0100 | -0.0100 | +0.0% |
| 2025-04-30 | 2025-06-13 | -0.0100 | -0.0200 | +50.0% |
Advertisement
Investor takeaway: Investors should note that Sernova's EPS has remained stable at -$0.01 for the last several quarters, suggesting a lack of growth momentum. However, recent developments, including a merger agreement and FDA designations, could present future opportunities for the company.
EPS Consistency at -$0.01 Over 20 Quarters
Sernova's EPS has been unchanged at -$0.01 for the last four quarters, highlighting a lack of growth in earnings despite ongoing operational activities.
Bull case
The merger with Seraxis to form BetaNova Biotherapeutics could boost Sernova's ability to develop innovative therapies for type 1 diabetes. This partnership might lead to long-term growth and increased interest from investors.
Bear case
With an EPS consistently at -$0.01 and no revenue reported in the latest quarter, Sernova faces significant challenges in proving its financial viability. Attracting new investment will be tough without a clear path to profitability.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
